Apomorphine subcutaneous - NeuroHealing Pharmaceuticals
Alternative Names: NH-001Latest Information Update: 02 Oct 2021
At a glance
- Originator NeuroHealing Pharmaceuticals
- Developer Cato Research; NeuroHealing Pharmaceuticals
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Coma
Highest Development Phases
- Suspended Coma
Most Recent Events
- 26 Apr 2013 NeuroHealing Pharmaceuticals suspends enrolment in its Phase-II trial for Coma in USA (NCT00761228)
- 23 May 2011 NeuroHealing Pharmaceuticals receives Orphan Drug status for apomorphine for Coma in European Union
- 16 May 2011 NeuroHealing Pharmaceuticals and Cato BioVentures (Cato Research) agree to co-develop apomorphine for Coma